ASSOCIATION OF PLASMA NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN WITH METABOLIC SYNDROME

This prospective hospital-based study conducted in Tikrit City aimed to investigate the role of Neutrophil gelatinase-associated lipocalin (NGAL ) and level of hemoglobin A1c and lipid profile concentrations in Metabolic syndrome (MetS) with hypertension and Diabetes mellitus (DM). Objective - estimate of serum Neutrophil gelatinase-associated lipocalin levels in Metabolic syndrome patients and the Control Group. The study included 60 patients with metabolic syndrome along with 30 healthy individuals as controls who were 18-50 years old; the samples were collected at a specific time (10 P.M. to 1 A.M.) from October 2023 to the end of November 2023 from Tikrit Teaching Hospital in Tikrit City and analyzed for various parameters. Patients with Metabolic Syndrome had their waist measured men as >102 cm (>40 in) and Women >88 cm (>35 in) and BMI >30 kg/m2 and/or waist ship ratio >0.9 in men and >0.85 in women. The mean serum level NGAL in patients with metabolic syndrome compared with the control group (523.12±271.8 versus 353.66± 151.0 pg/ml). The result was a significant difference (p<0.001). The study found that metabolic syndrome patients who had HbA1c% results were significantly different (p<0.001) compared with the control group. Also, the serum level lipid profile concentrations in patients with metabolic syndrome compared with the control group which was significantly different (p<0.001). The results of this research clearly indicate that a high level of NGAL associated with metabolic syndrome is a significant risk factor for the incidence and mortality of cardiovascular disease. Reducing the prevalence of cardiovascular disease in the general population should involve identifying, treating, and preventing the underlying risk factors of metabolic syndrome. Male obesity, diabetes, dyslipidemia, and hypertension are well-known main cardiovascular risk factors.